Endocrine Abstracts

Introduction: Continuous glucose monitoring systems (CGM) have revolutionized the monitoring of diabetes, allowing real-time measurement of interstitial glucose levels. Although these devices are suitable for patients on insulin therapy, they are not yet routinely used in an inpatient setting. The difficulty observed in the glycemic control of hospitalized patients under intensive insulin therapy led to the development of a protocol to study the application of CGM in these pat...

Introduction: In 2020, a group of experts proposed to change the term “non-alcoholic fatty liver disease” (NAFLD) to “metabolic-associated fatty liver disease” (MAFLD), which includes hepatic steatosis (HS) (using imaging or analytical scores) associated with overweight or obesity, type 2 diabetes (T2D), or the presence of two other metabolic disorders.Objectives: Analyse the impact of bariatric surgery on MAFLD.<p class="abstext"...

Introduction: Obesity is a chronic disease whose association with increased cardiovascular morbidity and mortality, including heart failure, is well established. Not only is obesity intricately connected with an increased prevalence of concurrent risk factors, such as coronary artery disease, hypertension, diabetes mellitus, and obstructive sleep apnea, but it also exerts a direct impact on myocardial structure and pump performance. Over time, prolonged obesity fosters cardiac...

Introduction: We conducted a prospective study to compare the efficacy of continuous glucose monitoring (CGM) devices versus capillary blood glucose (CBG) in the glycemic control of inpatient type 2 diabetes on intensive insulin therapy. The use of CGM was associated with improved glycemic control, including an increased time in range (TIR) and reduced hyperglycemic events, being safe concerning hypoglycemias. The present study is the cost-effectiveness analysis associated wit...

Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a promising class of medications, demonstrating a significant reduction in the risk of cardiovascular events. An associated consequence of SGLT2i is an increase in hematocrit levels, with cardiovascular outcome trials revealing frequent hematocrit mean elevations varying from +2.3% to 3.5%. This rise in hematocrit introduces a potential dilemma when evaluating the risk-benefit profile of SGLT2i i...

Introduction: The immune checkpoint inhibitors (ICI) are increasingly being used in the treatment of several malignancies. ICI are monoclonal antibodies that inhibit immune checkpoints, thus stimulating the action of the immune cells to attack the tumour cells. The overstimulation of the immune system can lead to several endocrinopathies, such as autoimmune diabetes, known as ICI-associated diabetes mellitus (ICIDM).Case Report: In September 2023, a 62-y...